Impact Therapeutics (HKG:7630) said the overallotment option of its Hong Kong initial public offering was fully exercised on Friday, according to a same-day Hong Kong bourse filing.

The Chinese biopharmaceutical company expects to raise about HK$119.5 million in additional net proceeds.

The exercise involved the issue of 6.3 million additional H-shares at HK$20.10 each, representing about 15% of the total offer shares initially available under the global offering.

Dealings in the overallotment shares are expected to begin on June 10, the filing said.